Information Provided By:
Fly News Breaks for November 20, 2019
TAST, NEX, KLAC, BCO, JNJ
Nov 20, 2019 | 10:11 EDT
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) initiated with an Overweight at Cantor Fitzgerald. 2. Brink's (BCO) initiated with a Buy at Goldman Sachs. 3. KLA-Tencor (KLAC) initiated with a Buy at Nomura Instinet. 4. NexTier Oilfield (NEX) initiated with a Buy at Citi. 5. Carrols Restaurant (TAST) initiated with a Buy at Craig-Hallum. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
News For JNJ;BCO;KLAC;NEX;TAST From the Last 2 Days
JNJ
May 23, 2022 | 06:31 EDT
SVB Leerink analyst David Risinger assumed coverage of Johnson & Johnson with an Outperform rating and $200 price target. His thesis is that J&J should outperform due to the company's ability to deliver consistent earnings growth and execute value-enhancing M&A. Excluding Consumer, which Johnson & Johnson will exit in 2023, Risinger projects 5-year CAGR revenue growth in the low-single digits and earnings growth in the mid-single digits. He expects Stelara biosimilar pressures to constrain Pharmaceutical revenue growth starting in September 2023. His 2025 Pharma sales projection of $56B is thus flat with his 2022 of $56B. But Medical Device sales to continue to grow in the mid-single digits % range, the analyst adds.